Sugi Predict

Sugi Predict / Compounds / SCHEMBL988147

SCHEMBL988147

SCHEMBL988147

CCC(=O)c1ccc(C(=O)OC)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.70
▸ SMN1; SMN2 Q16637 5/20 0.70
▸ NPC1 O15118 3/20 0.70
▸ RAB9A P51151 3/20 0.70
▸ MEN1 O00255 2/20 0.70
▸ KMT2A Q03164 2/20 0.70
▸ CA1 P00915 2/20 0.59
▸ CA2 P00918 2/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ CA12 O43570 1/20 0.59
▸ CA7 P43166 1/20 0.59
▸ CA9 Q16790 1/20 0.59
▸ CA14 Q9ULX7 1/20 0.59
▸ LOXL2 Q9Y4K0 1/20 0.57
▸ CYP1A2 P05177 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ TSHR P16473 1/20 0.56
▸ HPGD P15428 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11391147 0.86 CA1 (0.64) MAPTSMN1; SMN2NPC1RAB9AMEN1
Alcohol SCHEMBL11164959 0.84 CA1 (0.67) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL23600 0.83 CA1 (0.80) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL28993944 0.83 CA1 (0.80) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL941119 0.83 HSD17B3 (0.62) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL8051337 0.83 SMN1; SMN2 (0.70) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL31148953 0.83 MAPT (0.56) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL31148952 0.83 MAPT (0.56) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL13321969 0.83 BAZ2B (0.58) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL12160355 0.83 CA1 (0.59) MAPTSMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378209-B2 Protease inhibitors MEDIVIR AB (SE) 2025-08-05 — — US disclosed
CN-115477577-B New method for preparing 2-methyl-4-acetyl benzoic acid and derivatives thereof 台州臻挚生物科技有限公司 2024-03-15 — — CN disclosed
CN-116640100-A Solid-phase synthesis method of fluororalrana 河北圣雪大成制药有限责任公司 2023-08-25 — — CN disclosed
CN-115477577-A Novel method for preparing 2-methyl-4-acetylbenzoic acid and derivatives thereof 台州臻挚生物科技有限公司 2022-12-16 — — CN disclosed
US-20220332690-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2022-10-20 — — US disclosed
US-11312693-B2 Protease inhibitors MEDIVIR AB (SE) 2022-04-26 — — US disclosed
US-11312693-B2 Protease inhibitors MEDIVIR AB (SE) 2022-04-26 — — US disclosed
US-20210017140-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2021-01-21 — — US disclosed
US-20210017140-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2021-01-21 — — US disclosed
US-10780392-B2 Multi-stage membrane for N2 rejection AIR LIQUIDE ADVANCED TECHNOLOGIES U.S. LLC (US) 2020-09-22 — — US disclosed
EP-1737826-A1 ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES TANABE SEIYAKU CO., LTD. (JP) 2007-01-03 — — EP disclosed
EP-1701960-A1 CYSTEINE PROTEASE INHIBITORS Medivir Aktiebolag (SE) 2006-09-20 — — EP disclosed
US-20060111272-A1 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation CHELSEA THERAPEUTICS, INC. 2006-05-25 — — US disclosed
WO-2006029385-A2 QUINAZOLINE DERIVATIVES AS METABOLICALLY INERT ANTIFOLATE COMPOUNDS. CHELSEA THERAPEUTICS, INC. (US) 2006-03-16 — — WO disclosed
WO-2005075438-A1 ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES TANABE SEIYAKU CO., LTD. (JP) 2005-08-18 — — WO disclosed
WO-2005066180-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2005-07-21 — — WO disclosed
EP-1535911-A1 Metabolically inert anti-inflammatory and anti-tumor antifolates NAIR, Madhavan G. (US) 2005-06-01 — — EP disclosed
US-5912251-A ENZYME INHIBITORS CHELSEA THERAPEUTICS, INC. 1999-06-15 — — US disclosed
WO-1993013102-A1 DEAZAAMINOPTERINS SOUTHERN RESEARCH INSTITUTE (US) 1993-07-08 — — WO disclosed
US-5077404-A Cyclized 5,10-dideazaaminopterin compounds SRI INTERNATIONAL 1991-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312693-B2 Protease inhibitors CTSK, CTSF, CTSS MAPT 4466/4885SMN1; SMN2 2722/4885NPC1 303/4885
US-20060111272-A1 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation DHFR, MTHFD1, MTHFD2 MAPT 816/4885SMN1; SMN2 4435/4885NPC1 1412/4885
US-12378209-B2 Protease inhibitors MMP26, CTSK, TMPRSS6 MAPT 4529/4885SMN1; SMN2 2789/4885NPC1 375/4885
US-20210017140-A1 PROTEASE INHIBITORS CTSK, CTSF, CTSS MAPT 4466/4885SMN1; SMN2 2722/4885NPC1 303/4885
US-20220332690-A1 PROTEASE INHIBITORS MMP26, CTSK, TMPRSS6 MAPT 4529/4885SMN1; SMN2 2789/4885NPC1 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.